Collegium Q3 revenue rises 3% to $216.3 million; adjusted EBITDA falls 9%
Collegium Pharmaceutical reported third-quarter 2026 product revenues of $216.3 million, up 3% from a year earlier, but GAAP diluted earnings per share fell to $0.60 from $0.84 and adjusted EBITDA fell 9% to $121.6 million. The company reaffirmed its full-year 2026 guidance and said it expects to complete a $50 million accelerated share repurchase before the end of the year.
Key points
- Product revenues, net were $216.3 million versus $209.4 million a year earlier; JORNAY PM net revenue rose 24% to $51.9 million.
- GAAP net income was $21.8 million, or $0.60 diluted EPS, compared with $31.5 million, or $0.84, in the third quarter of 2025.
- Adjusted EBITDA was $121.6 million, down from $133.0 million; full-year 2026 adjusted EBITDA guidance of $445 million to $470 million was reaffirmed.
- Pain portfolio net revenues fell 18% to $138.0 million, while AZSTARYS contributed $26.5 million in its first full quarter under Collegium ownership.
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 7, 2026, 11:17 PM ET, from the text of the filing and its press-release exhibits only.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.